172 related articles for article (PubMed ID: 2449084)
1. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
Kawai T; Greenberg SD; Truong LD; Mattioli CA; Klima M; Titus JL
Am J Pathol; 1988 Feb; 130(2):401-10. PubMed ID: 2449084
[TBL] [Abstract][Full Text] [Related]
2. Expression of blood group-related antigens and Helix pomatia agglutinin in malignant pleural mesothelioma and pulmonary adenocarcinoma.
Kawai T; Suzuki M; Torikata C; Suzuki Y
Hum Pathol; 1991 Feb; 22(2):118-24. PubMed ID: 2001875
[TBL] [Abstract][Full Text] [Related]
3. Lectin histochemistry of normal lung and pulmonary adenocarcinoma.
Kawai T; Greenberg SD; Titus JL
Mod Pathol; 1988 Nov; 1(6):485-92. PubMed ID: 3222257
[TBL] [Abstract][Full Text] [Related]
4. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
Sheibani K; Battifora H; Burke JS
Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
[TBL] [Abstract][Full Text] [Related]
5. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas.
Corson JM; Pinkus GS
Am J Pathol; 1982 Jul; 108(1):80-8. PubMed ID: 6178295
[TBL] [Abstract][Full Text] [Related]
6. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J
Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry in the diagnosis of malignant mesothelioma.
Pfaltz M; Odermatt B; Christen B; Rüttner JR
Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
Han AC; Peralta-Soler A; Knudsen KA; Wheelock MJ; Johnson KR; Salazar H
Hum Pathol; 1997 Jun; 28(6):641-5. PubMed ID: 9190996
[TBL] [Abstract][Full Text] [Related]
10. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
11. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
al-Saffar N; Hasleton PS
Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
[TBL] [Abstract][Full Text] [Related]
12. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
13. Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma.
Epstein JI; Budin RE
Hum Pathol; 1986 May; 17(5):514-9. PubMed ID: 2422109
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of membranous staining of mesothelioma.
King JA; Tucker JA
Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
[TBL] [Abstract][Full Text] [Related]
15. Immunohistological study of malignant diffuse mesotheliomas of the pleura.
Loosli H; Hurlimann J
Histopathology; 1984 Sep; 8(5):793-803. PubMed ID: 6083969
[TBL] [Abstract][Full Text] [Related]
16. TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma.
Bakir K; Koçer NE; Deniz H; Güldür ME
Ann Diagn Pathol; 2004 Dec; 8(6):337-41. PubMed ID: 15614737
[TBL] [Abstract][Full Text] [Related]
17. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
Ordóñez NG
Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
[TBL] [Abstract][Full Text] [Related]
18. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
Roberts F; Harper CM; Downie I; Burnett RA
Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma.
Holden J; Churg A
Am J Surg Pathol; 1984 Apr; 8(4):277-9. PubMed ID: 6201076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]